Phuturdex › Diseases › Psoriasis
Drugs in development · updated 30 October 2026
Psoriasis: drugs in development
As of 30 October 2026 there are 48 active clinical trials (recruiting or ongoing, phases I–III) on 46 drugs for psoriasis. 26 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| HS-10374 | III | 2 | NCT06672393 |
| SFA002 | II–III | 2 | NCT06863493 |
| IBI112 | III | 1 | NCT07265284 |
| JNJ-77242113 | III | 1 | NCT06295692 |
| Piclidenoson | III | 1 | NCT06643260 |
| Sulodexide | III | 1 | NCT06982196 |
| TQH3906 | III | 1 | NCT07724366 |
| ZasocitinibTAK-279 | III | 1 | NCT07752108 |
| HSK44459 | I–II | 2 | NCT07623486 |
| CBP-0276 | II | 1 | NCT07204639 |
| D-2570 | II | 1 | NCT07489885 |
| DDY391 | II | 1 | NCT07801495 |
| HB0034 | II | 1 | NCT06231381 |
| Salicylic Acid | II | 1 | NCT07841314 |
| HS-20118 | I | 2 | NCT06846710 |
| ABBV-547 | I | 1 | NCT07232004 |
| CKD-704 | I | 1 | NCT07258745 |
| Fluoropyrimidine | I | 1 | NCT03816345 |
| HCXT-2001 | I | 1 | NCT07792928 |
| Hemay005 | I | 1 | NCT06376474 |
| HL40626S | I | 1 | NCT07736586 |
| LPX-TI641 | I | 1 | NCT06982352 |
| MK-8644 | I | 1 | NCT07850310 |
| S-4321 | I | 1 | NCT07455578 |
| SHR-1139 | I | 1 | NCT07078695 |
| TQH2929 | I | 1 | NCT06433531 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| DeucravacitinibBMS-986165, Sotyktu® | III | 4 | NCT06979453 |
| BimekizumabBimzelx® | III | 3 | NCT06425549 |
| RisankizumabSKYRIZI | III | 2 | NCT04862286 |
| TofacitinibXeljanz®, Inijaq® | III | 2 | NCT07530367 |
| UstekinumabPyzchiva®, Starjemza® | III | 2 | NCT06425549 |
| ApremilastOtezla, Apremilast Accord® | II–III | 1 | NCT06863493 |
| EtanerceptEticovo®, Erelzi® | III | 1 | NCT03451851 |
| GuselkumabTremfya | III | 1 | NCT03451851 |
| ImatinibSTI571, Imkeldi® | III | 1 | NCT07530367 |
| PonesimodPonvory® | III | 1 | NCT07362017 |
| SemaglutideWegovy, Rybelsus | III | 1 | NCT06937060 |
| Tacrolimus ointment 0.1% | III | 1 | NCT07892339 |
| ClobetasolClobetasol Propionate, Byqlovi® | II | 1 | NCT06742333 |
| DelgocitinibAnzupgo® | II | 1 | NCT07013201 |
| RoflumilastZoryve®, Daliresp® | II | 1 | NCT07233291 |
Sorted by most advanced phase and number of active trials. Showing 15 of 20 drugs.
All 46 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Psoriatic arthritis 48 drugs
- Rheumatoid arthritis 130 drugs
- Arthritis, Juvenile 39 drugs
- Axial spondyloarthritis 5 drugs
- Rheumatic Diseases 30 drugs
- Crohn's disease 81 drugs
- Ulcerative colitis 99 drugs
- Ankylosing spondylitis 31 drugs
- Systemic lupus erythematosus 178 drugs
- Spondylarthritis 27 drugs
- Polymyalgia rheumatica 30 drugs
- Giant cell arteritis 30 drugs
Broader categories
- Skin and connective tissue diseases 3 drugs
- Skin disease 34 drugs
- Immune System Diseases 54 drugs
- Joint Diseases 6 drugs
- Musculoskeletal disorder 22 drugs
- Arthritis 13 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D011565 “Psoriasis”.